Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTRL | P40313 | 2/20 | 0.80 |
| ▸ | TMPRSS11D | O60235 | 1/20 | 0.80 |
| ▸ | PSMB5 | P28074 | 16/20 | 0.79 |
| ▸ | PSMB9 | P28065 | 3/20 | 0.79 |
| ▸ | PSMB8 | P28062 | 3/20 | 0.79 |
| ▸ | PSMB10 | P40306 | 3/20 | 0.79 |
| ▸ | PSMB2 | P49721 | 3/20 | 0.79 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.79 |
| ▸ | CYP3A5 | P20815 | 2/20 | 0.79 |
| ▸ | CYP3A7 | P24462 | 2/20 | 0.79 |
| ▸ | CYP3A43 | Q9HB55 | 2/20 | 0.79 |
| ▸ | PSMB11 | A5LHX3 | 1/20 | 0.79 |
| ▸ | PSMD11 | O00231 | 1/20 | 0.79 |
| ▸ | PSMD12 | O00232 | 1/20 | 0.79 |
| ▸ | PSMD14 | O00487 | 1/20 | 0.79 |
| ▸ | PSMA7 | O14818 | 1/20 | 0.79 |
| ▸ | PSMD3 | O43242 | 1/20 | 0.79 |
| ▸ | CTSB | P07858 | 1/20 | 0.79 |
| ▸ | PSMC3 | P17980 | 1/20 | 0.79 |
| ▸ | PSMB1 | P20618 | 1/20 | 0.79 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20825238 | 1.00 | CTRL (0.80) | CTRLTMPRSS11DPSMB5PSMB9PSMB8 | |
| SCHEMBL15413127 | 1.00 | CTRL (0.80) | CTRLTMPRSS11DPSMB5PSMB9PSMB8 | |
| SCHEMBL20218351 | 1.00 | CTRL (0.80) | CTRLTMPRSS11DPSMB5PSMB9PSMB8 | |
| SCHEMBL18257553 | 1.00 | CTRL (0.80) | CTRLTMPRSS11DPSMB5PSMB9PSMB8 | |
| SCHEMBL18257561 | 1.00 | CTRL (0.80) | CTRLTMPRSS11DPSMB5PSMB9PSMB8 | |
| SCHEMBL23616318 | 1.00 | CTRL (0.80) | CTRLTMPRSS11DPSMB5PSMB9PSMB8 | |
| SCHEMBL8080983 | 1.00 | CTRL (0.80) | CTRLTMPRSS11DPSMB5PSMB9PSMB8 | |
| SCHEMBL8075093 | 1.00 | CTRL (0.80) | CTRLTMPRSS11DPSMB5PSMB9PSMB8 | |
| SCHEMBL20825237 | 0.95 | TMPRSS11D (0.75) | CTRLTMPRSS11DPSMB5PSMB9PSMB8 | |
| SCHEMBL19851642 | 0.95 | TMPRSS11D (0.75) | CTRLTMPRSS11DPSMB5PSMB9PSMB8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 119 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10544189-B2 | Process for the preparation of (2S)-N-((S)-1-((S)-4-methyl-1-((R)-2-methyl oxiran-2-yl)-1-oxopentan-2-ylcarbamoyl)-2-phenylethyl)-2-((S)-2-(2-morpholinoacetamido)-4-phenylbutanamido)-4-methylpentanamide | MSN LABORATORIES PRIVATE LIMITED (IN) | 2020-01-28 | — | — | US | claimed |
| US-10301353-B2 | Co-crystal of carfilzomib with maleic acid and process for the preparation of pure carfilzomib | DR. REDDY'S LABORATORIES LIMITED (IN) | 2019-05-28 | — | — | US | claimed |
| US-20180298056-A1 | PROCESS FOR THE PREPARATION OF (2S)-N-((S)-1-((S)-4-METHYL-1-((R)-2-METHYL OXIRAN-2-YL)-1-OXOPENTAN-2-YLCARBAMOYL)-2-PHENYLETHYL)-2-((S)-2-(2-MORPHOLINO ACETAMIDO)-4-PHENYLBUTANAMIDO)-4-METHYLPENTANAMIDE | MSN LABORATORIES PRIVATE LIMITED (IN) | 2018-10-18 | — | — | US | claimed |
| US-20170369528-A1 | CO-CRYSTAL OF CARFILZOMIB WITH MALEIC ACID AND PROCESS FOR THE PREPARATION OF PURE CARFILZOMIB | DR. REDDY'S LABORATORIES LIMITED (IN) | 2017-12-28 | — | — | US | claimed |
| EP-3240575-A1 | CO-CRYSTAL OF CARFILZOMIB WITH MALEIC ACID AND PROCESS FOR THE PREPARATION OF PURE CARFILZOMIB | Dr. Reddy's Laboratories Ltd. (IN) | 2017-11-08 | — | — | EP | claimed |
| WO-2016170544-A1 | PROCESS FOR THE PREPARATION OF (2S)-N-((S)-1-((S)-4-METHYL-1-((R)-2-METHYL OXIRAN-2-YL)-1-OXOPENTAN-2-YLCARBAMOYL)-2-PHENYLETHYL)-2-((S)-2-(2-MORPHOLINO ACETAMIDO)-4-PHENYLBUTANAMIDO)-4-METHYLPENTANAMIDE | MSN LABORATORIES PRIVATE LIMITED (IN) | 2016-10-27 | — | — | WO | claimed |
| WO-2016108204-A1 | CO-CRYSTAL OF CARFILZOMIB WITH MALEIC ACID AND PROCESS FOR THE PREPARATION OF PURE CARFILZOMIB | DR. REDDY'S LABORATORIES LIMITED (IN) | 2016-07-07 | — | — | WO | claimed |
| US-20260014226-A1 | STABLE READY TO DILUTE COMPOSITION OF CARFILZOMIB | KASHIV BIOSCIENCES LLC (US) | 2026-01-15 | — | — | US | disclosed |
| US-12440534-B2 | Stable ready to dilute composition of carfilzomib | KASHIV BIOSCIENCES, LLC (US) | 2025-10-14 | — | — | US | disclosed |
| EP-4419080-A1 | STABLE READY TO DILUTE COMPOSITION OF CARFILZOMIB | Kashiv Biosciences, LLC (US) | 2024-08-28 | — | — | EP | disclosed |
| US-20240269224-A1 | STABLE READY TO DILUTE COMPOSITION OF CARFILZOMIB | ACQUIOM AGENCY SERVICES, AS COLLATERAL AGENT | 2024-08-15 | — | — | US | disclosed |
| CN-118434408-A | Stable instant diluted composition of carfilzomib | 卡希夫生物科学有限公司 | 2024-08-02 | — | — | CN | disclosed |
| US-20230158099-A1 | STABLE READY TO DILUTE FORMULATIONS OF CARFILZOMIB | ACQUIOM AGENCY SERVICES, AS COLLATERAL AGENT | 2023-05-25 | — | — | US | disclosed |
| US-20080200398-A1 | Compounds For Enzyme Inhibition | PROTEOLIX, INC. (US) | 2008-08-21 | — | — | US | disclosed |
| US-20080200398-A1 | Compounds For Enzyme Inhibition | PROTEOLIX, INC. (US) | 2008-08-21 | — | — | US | disclosed |
| US-20070191284-A1 | Peptide-based compounds include at least three peptide units, an epoxide or aziridine, and functionalization at the N-terminus inhibit specific activities of N-terminal nucleophile (Ntn) hydrolases, e.g., the chymotrypsin-like activity of the 20S proteasome; antiproliferative and antiinflammatory agents | PROTEOLIX, INC. (US) | 2007-08-16 | — | — | US | disclosed |
| US-20070191284-A1 | Peptide-based compounds include at least three peptide units, an epoxide or aziridine, and functionalization at the N-terminus inhibit specific activities of N-terminal nucleophile (Ntn) hydrolases, e.g., the chymotrypsin-like activity of the 20S proteasome; antiproliferative and antiinflammatory agents | PROTEOLIX, INC. (US) | 2007-08-16 | — | — | US | disclosed |
| US-7232818-B2 | Peptide-based compounds include at least three peptide units, an epoxide or aziridine, and functionalization at the N-terminus inhibit specific activities of N-terminal nucleophile (Ntn) hydrolases, e.g., the chymotrypsin-like activity of the 20S proteasome; antiproliferative and antiinflammatory agents | PROTEOLIX, INC. (US) | 2007-06-19 | — | — | US | disclosed |
| US-7232818-B2 | Peptide-based compounds include at least three peptide units, an epoxide or aziridine, and functionalization at the N-terminus inhibit specific activities of N-terminal nucleophile (Ntn) hydrolases, e.g., the chymotrypsin-like activity of the 20S proteasome; antiproliferative and antiinflammatory agents | PROTEOLIX, INC. (US) | 2007-06-19 | — | — | US | disclosed |
| US-20060030533-A1 | Peptide-based compounds include at least three peptide units, an epoxide or aziridine, and functionalization at the N-terminus inhibit specific activities of N-terminal nucleophile (Ntn) hydrolases, e.g., the chymotrypsin-like activity of the 20S proteasome; antiproliferative and antiinflammatory agents | PROTEOLIX, INC. (US) | 2006-02-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10544189-B2 | Process for the preparation of (2S)-N-((S)-1-((S)-4-methyl-1-((R)-2-methyl oxiran-2-yl)-1-oxopentan-2-ylcarbamoyl)-2-phenylethyl)-2-((S)-2-(2-morpholinoacetamido)-4-phenylbutanamido)-4-methylpentanamide | OPRL1, PNMT, HTR1A | CTRL 2898/4885TMPRSS11D 1591/4885PSMB5 448/4885 |
| US-20080200398-A1 | Compounds For Enzyme Inhibition | ANPEP, DNPEP, CPN1 | CTRL 4/4885TMPRSS11D 282/4885PSMB5 24/4885 |
| US-20260014226-A1 | STABLE READY TO DILUTE COMPOSITION OF CARFILZOMIB | KIT, CFH, CFD | CTRL 84/4885TMPRSS11D 615/4885PSMB5 1201/4885 |
| US-20180298056-A1 | PROCESS FOR THE PREPARATION OF (2S)-N-((S)-1-((S)-4-METHYL-1-((R)-2-METHYL OXIRAN-2-YL)-1-OXOPENTAN-2-YLCARBAMOYL)-2-PHENYLETHYL)-2-((S)-2-(2-MORPHOLINO ACETAMIDO)-4-PHENYLBUTANAMIDO)-4-METHYLPENTANAMIDE | OPRL1, OPRM1, ADRA1D | CTRL 2820/4885TMPRSS11D 1567/4885PSMB5 487/4885 |
| US-20170369528-A1 | CO-CRYSTAL OF CARFILZOMIB WITH MALEIC ACID AND PROCESS FOR THE PREPARATION OF PURE CARFILZOMIB | PRCP, ME1, MAN2B1 | CTRL 13/4885TMPRSS11D 930/4885PSMB5 91/4885 |
| US-10301353-B2 | Co-crystal of carfilzomib with maleic acid and process for the preparation of pure carfilzomib | PRCP, ME1, MAN2B1 | CTRL 13/4885TMPRSS11D 930/4885PSMB5 91/4885 |
| US-20060030533-A1 | Peptide-based compounds include at least three peptide units, an epoxide or aziridine, and functionalization at the N-terminus inhibit specific activities of N-terminal nucleophile (Ntn) hydrolases, e.g., the chymotrypsin-like activity of the 20S proteasome; antiproliferative and antiinflammatory agents | ANPEP, DNPEP, CPN1 | CTRL 10/4885TMPRSS11D 386/4885PSMB5 23/4885 |
| US-20070191284-A1 | Peptide-based compounds include at least three peptide units, an epoxide or aziridine, and functionalization at the N-terminus inhibit specific activities of N-terminal nucleophile (Ntn) hydrolases, e.g., the chymotrypsin-like activity of the 20S proteasome; antiproliferative and antiinflammatory agents | ANPEP, DNPEP, PSMB1 | CTRL 8/4885TMPRSS11D 388/4885PSMB5 21/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.